Esophageal squamous cell carcinoma (esophageal squamous cell carcinoma, ESCC) is a common, highly prevalent, and lethal histologic subtype of esophageal cancer, and it is often used as the disease context for biomarker discovery and perioperative treatment studies. Its biology is shaped by a heterogeneous tumor immune microenvironment, which influences tumor behavior, clinical benefit, and immunotherapy prognosis, and multi-omics work has also examined panoptosis related genes as prognostic markers. Recent literature emphasizes immunotherapy-era management, including immune checkpoint inhibitors, neoadjuvant immunotherapy combined with chemotherapy, adjuvant immunotherapy, and tislelizumab in unresectable locally advanced disease. The disease is also being studied with dynamic circulating tumor dna approaches to refine perioperative patient selection, and with persistent tumor antigens after neoadjuvant therapy to support tumor associated antigen vaccination. A review also discusses a possible association with human papillomavirus, although the epidemiologic evidence is heterogeneous. Overall, ESCC research is moving toward precision, multimodal, and organ-preserving strategies, including surgery-as-needed approaches in selected patients.
Immunotherapy and perioperative management
- A 2026 Journal of Clinical Oncology phase II trial (PMID:41962116) evaluated tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy in unresectable locally advanced ESCC.
- A 2026 review on perioperative management in the immunotherapy era (PMID:41978394) highlighted neoadjuvant immunotherapy combined with chemotherapy, adjuvant immunotherapy, and active surveillance/surgery-as-needed strategies.
- A 2026 Annals of Medicine study in elderly patients (PMID:41626750) assessed adding anti pd 1 antibody to definitive chemoradiotherapy and concluded that higher intensity did not necessarily improve outcomes.
- A 2026 Journal for Immunotherapy of Cancer article (PMID:41986074) used thoracic malignancy/ESCC as the clinical example for interpretable multimodal radiopathomics in the neoadjuvant immunotherapy era.
Biomarkers, immune microenvironment, and multi-omics
- A 2026 Frontiers in Oncology study (PMID:41930201) analyzed panoptosis related genes in ESCC/ESCA as prognostic biomarkers with therapeutic significance.
- A 2026 Cancer Biology & Therapy review (PMID:41814475) summarized the compositional heterogeneity of the tumor immune microenvironment and its role in immunopredictive models.
- A 2026 EMBO Molecular Medicine study (PMID:41965870) integrated proteome, phosphoproteome, and immunohistochemistry data to define proteomic subtypes and predictors of immunotherapy response, linking mitochondrial complex I to treatment response.
- A 2026 International Journal of Oncology review (PMID:42028731) discussed multi-omics biomarker discovery and the possible role of human papillomavirus in ESCC.
Neoadjuvant response, residual disease, and antigen persistence
- A 2026 Journal for Immunotherapy of Cancer study (PMID:42019971) used single-cell analysis to identify persistent tumor antigens in non-responders after neoadjuvant therapy, supporting tumor associated antigen vaccination.
- The same study (PMID:42019971) specifically framed these findings as opportunities for post-neoadjuvant vaccination strategies in ESCC.
- A 2026 review on pathogenesis and precision therapies (PMID:41986343) discussed ESCC as a major histologic subtype of esophageal cancer in the context of tumor initiation and progression.
- The perioperative management review (PMID:41978394) also emphasized dynamic biomarkers such as circulating tumor dna to refine selection after neoadjuvant treatment.